Skip to main content

Advertisement

SpringerLink
Log in

Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The separation of myelodysplastic syndromes from acute myeloid leukemia has been problematic because, as clinical entities, they represent different points in the spectrum of the same disease process. A new classification by the World Health Organization has incorporated recent prognostic findings in myelodysplastic syndrome and distinct genetic subtypes of acute myelogenous leukemia to provide an improved conceptual framework, if not a simpler nomenclature. Here, we review the new classification system and discuss its impact on diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Heaney ML, Golde DW: Myelodysplasia. N Engl J Med 1999, 340:1649–1660. This is a review of myelodysplastic syndrome with current references accessible to the generalist.

    Article  PubMed  CAS  Google Scholar 

  2. Gralnick HR, Galton DAG, Catovsky D, et al.: Classification of acute leukemia. Ann Intern Med 1977, 87:740–753.

    Google Scholar 

  3. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189–199.

    PubMed  CAS  Google Scholar 

  4. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079–2088.

    PubMed  CAS  Google Scholar 

  5. De Witte T, Suciu S, Peetermans M, et al.: Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration: a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995, 9:1805–1811.

    PubMed  Google Scholar 

  6. Estey E, Thall P, Beran M, et al.: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type therapy. Blood 1997, 90:2969–2977.

    PubMed  CAS  Google Scholar 

  7. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Adisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835–3849. This publication offers a comprehensive classification of hematologic malignancies. The REAL classification is adopted for lymphoid malignancies but other neoplasms of the blood cell are categorized, including myeloid malignancies. An attempt is made to correlate pathologic diagnoses with discreet clinical entities. Discussion of new classifications and areas of controversy is also included. A more complete description will be provided in a WHO handbook.

    PubMed  CAS  Google Scholar 

  8. Nimer SD, Golde DW: The 5q-abnormality. Blood 1987, 70:1705–1712.

    PubMed  CAS  Google Scholar 

  9. Boultwood J, Lewis S, Wainscoat JS: The 5q-syndrome. Blood 1994, 84:3253–3260.

    PubMed  CAS  Google Scholar 

  10. Stein RS, Abels RI, Krantz SB: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991, 78:1658–1663.

    PubMed  CAS  Google Scholar 

  11. Rose EH, Abels RI, Nelson RA, et al.: The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995, 89:831–837.

    Article  PubMed  CAS  Google Scholar 

  12. Hellstrom-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995, 89:67–71.

    PubMed  CAS  Google Scholar 

  13. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al.: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995, 86:3542–3552.

    PubMed  CAS  Google Scholar 

  14. Molldrem JJ, Caples M, Mavroudis D, et al.: Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699–705.

    Article  PubMed  CAS  Google Scholar 

  15. Jonásová A, Neuwirtová R, Cermák J, et al.: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 100:304–309.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Program in Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Mark L. Heaney MD, PhD & David W. Golde MD

Authors
  1. Mark L. Heaney MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David W. Golde MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heaney, M.L., Golde, D.W. Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. Curr Oncol Rep 2, 140–143 (2000). https://doi.org/10.1007/s11912-000-0085-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-000-0085-x

Keywords

Search

Navigation